RxSight Lowers Full-Year Sales Guidance Amidst Q2 Commercial Headwinds
RXST sits 24% above its 52-week low of $4.48.
Summary
RxSight reported preliminary Q2 results and cut its full-year sales guidance, citing competitive pressures, despite new collaboration revenue and improved gross margin outlook.
Key Events · Earnings and Guidance · RXST
-
Preliminary Q2 Revenue Announced
Total company revenue is expected to be approximately $32 million to $34 million for Q2 2026, including $5 million to $7 million from the Alcon Strategic Collaboration.
-
Full-Year Sales Guidance Lowered
2026 full-year sales guidance (excluding collaboration revenue) was lowered to $110 million to $120 million, down from previous guidance of $120 million to $135 million.
-
Gross Margin Guidance Raised
Full-year gross margin guidance was increased to 73% to 75%, up from previous guidance of 70% to 72%.
-
Strong Cash Position
The company reported approximately $209 million in cash, cash equivalents, and short-term investments as of June 30, 2026.
Analysis · RXST · Industrial Applications And Services
RxSight announced preliminary Q2 results and updated 2026 guidance, lowering its full-year sales forecast due to "meaningful commercial headwinds" and increased competitive trialing. While the company expects new revenue from its Alcon collaboration and raised its gross margin outlook, the reduction in core product sales guidance indicates a slowdown in its primary business. The company maintains a strong cash position, providing financial flexibility.
At the time of this filing, RXST was trading at $5.54 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $231.8M. The 52-week trading range was $4.48 to $13.65. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.